Artelo biosciences to present preclinical data showcasing research on art26.12 and art12.11 in anxiety and depression at neuroscience 2023

Solana beach, calif., nov. 02, 2023 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that the research group working with steven laviolette, ph.d., scientific advisor at artelo biosciences and professor in the schulich school of medicine at the university of western ontario, canada, will be presenting at neuroscience 2023. the conference will be hosted by the society for neuroscience and held november 11-15, 2023 at the walter e. washington convention center in washington, d.c. neuroscience 2023 is the world's largest source of emerging news on brain science and health, with 25,000 neuroscience researchers and clinicians expected in attendance.
ARTL Ratings Summary
ARTL Quant Ranking